Jim Simons’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $57.9M | Sell |
1,024,871
-300,100
| -23% | -$17.5M | 0.09% | 281 |
|
|
2025
Q4 | $78.7M | Sell |
1,324,971
-568,600
| -30% | -$31M | 0.12% | 189 |
|
|
2025
Q3 | $103M | Buy |
1,893,571
+86,800
| +5% | +$4.96M | 0.14% | 160 |
|
|
2025
Q2 | $99.3M | Buy |
1,806,771
+911,000
| +102% | +$53.6M | 0.13% | 159 |
|
|
2025
Q1 | $63.3M | Buy |
895,771
+459,900
| +106% | +$30.9M | 0.1% | 252 |
|
|
2024
Q4 | $28.6M | Buy |
435,871
+17,000
| +4% | +$1.14M | 0.04% | 502 |
|
|
2024
Q3 | $29.4M | Buy |
418,871
+302,671
| +260% | +$25.3M | 0.04% | 501 |
|
|
2024
Q2 | $9.57M | Sell |
116,200
-425,871
| -79% | -$35.5M | 0.02% | 952 |
|
|
2024
Q1 | $47.3M | Buy |
542,071
+155,400
| +40% | +$13.9M | 0.07% | 320 |
|
|
2023
Q4 | $37.3M | Sell |
386,671
-195,100
| -34% | -$17.3M | 0.06% | 383 |
|
|
2023
Q3 | $51.5M | Sell |
581,771
-150,867
| -21% | -$13.4M | 0.09% | 252 |
|
|
2023
Q2 | $63.5M | Sell |
732,638
-48,433
| -6% | -$4.56M | 0.09% | 246 |
|
|
2023
Q1 | $76M | Buy |
781,071
+150,800
| +24% | +$15.6M | 0.1% | 239 |
|
|
2022
Q4 | $65.2M | Sell |
630,271
-114,200
| -15% | -$10.7M | 0.09% | 254 |
|
|
2022
Q3 | $63.1M | Buy |
744,471
+9,708
| +1% | +$864K | 0.09% | 267 |
|
|
2022
Q2 | $60.9M | Buy |
734,763
+243,592
| +50% | +$19.4M | 0.07% | 314 |
|
|
2022
Q1 | $37.9M | Sell |
491,171
-159,889
| -25% | -$13.4M | 0.04% | 443 |
|
|
2021
Q4 | $57.5M | Buy |
651,060
+269,589
| +71% | +$22.2M | 0.07% | 293 |
|
|
2021
Q3 | $29.5M | Buy |
381,471
+91,500
| +32% | +$7.22M | 0.04% | 493 |
|
|
2021
Q2 | $24.2M | Sell |
289,971
-75,600
| -21% | -$5.99M | 0.03% | 647 |
|
|
2021
Q1 | $27.6M | Buy |
+365,571
| New | +$29.9M | 0.03% | 604 |
|
|
2020
Q2 | – | Sell |
-19,100
| Closed | -$1.61M | – | 3445 |
|
|
2020
Q1 | $1.61M | Sell |
19,100
-183,371
| -91% | -$15.8M | ﹤0.01% | 2171 |
|
|
2019
Q4 | $17.1M | Sell |
202,471
-353,600
| -64% | -$26.7M | 0.01% | 1091 |
|
|
2019
Q3 | $37.5M | Buy |
556,071
+18,700
| +3% | +$1.44M | 0.03% | 613 |
|
|
2019
Q2 | $46M | Buy |
537,371
+215,400
| +67% | +$18.4M | 0.04% | 529 |
|
|
2019
Q1 | $28.6M | Buy |
321,971
+278,400
| +639% | +$25.8M | 0.03% | 781 |
|
|
2018
Q4 | $3.71M | Sell |
43,571
-163,400
| -79% | -$15.5M | ﹤0.01% | 1909 |
|
|
2018
Q3 | $20.1M | Buy |
206,971
+178,500
| +627% | +$17.8M | 0.02% | 927 |
|
|
2018
Q2 | $2.68M | Sell |
28,471
-100,100
| -78% | -$8.77M | ﹤0.01% | 2124 |
|
|
2018
Q1 | $10.4M | Sell |
128,571
-132,800
| -51% | -$11.4M | 0.01% | 1339 |
|
|
2017
Q4 | $23.3M | Sell |
261,371
-58,900
| -18% | -$5.12M | 0.03% | 845 |
|
|
2017
Q3 | $29.8M | Buy |
320,271
+193,400
| +152% | +$17.1M | 0.04% | 666 |
|
|
2017
Q2 | $11.5M | Buy |
+126,871
| New | +$11.5M | 0.01% | 1190 |
|
|
2017
Q1 | – | Sell |
-39,371
| Closed | -$3.26M | – | 3230 |
|
|
2016
Q4 | $3.26M | Buy |
+39,371
| New | +$3.39M | 0.01% | 1949 |
|
|
2016
Q2 | – | Sell |
-132,071
| Closed | -$10.9M | – | 3333 |
|
|
2016
Q1 | $10.9M | Sell |
132,071
-61,500
| -32% | -$5M | 0.02% | 1082 |
|
|
2015
Q4 | $20.3M | Sell |
193,571
-69,000
| -26% | -$7.21M | 0.04% | 538 |
|
|
2015
Q3 | $27.7M | Buy |
262,571
+138,900
| +112% | +$18.6M | 0.07% | 368 |
|
|
2015
Q2 | $16.9M | Buy |
+123,671
| New | +$15.3M | 0.04% | 638 |
|
|
2014
Q1 | – | Sell |
-280,071
| Closed | -$19.7M | – | 2828 |
|
|
2013
Q4 | $19.7M | Buy |
+280,071
| New | +$19M | 0.05% | 472 |
|
Other funds holding BMRN
VCM
VPM
Jim Simons's BMRN Position: Q1 2026 in Review
Jim Simons reduced its BioMarin Pharmaceuticals (BMRN) stake by 23% in Q1 2026, selling an estimated $17.5M and leaving 1,024,871 shares worth $57.9M. The position accounts for 0.09% of the portfolio, ranked #281.
Jim Simons first reported a position in BMRN in Q4 2013 and has held it in 39 quarters since. The position peaked at $103M in Q3 2025. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Jim Simons held 1,024,871 shares of BioMarin Pharmaceuticals worth $57.9M as of Q1 2026.
- Jim Simons sold 300,100 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $17.5M.
- BioMarin Pharmaceuticals made up 0.09% of Jim Simons's portfolio in Q1 2026, its #281 holding.
- Jim Simons first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 39 quarters since.
- Jim Simons's BioMarin Pharmaceuticals position peaked at $103M in Q3 2025.
- 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.